BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36302174)

  • 21. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
    Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
    Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
    Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
    Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
    El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
    Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
    Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
    Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
    Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
    Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
    Lalazar G; Simon SM
    Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracranial metastasis in fibrolamellar hepatocellular carcinoma.
    Hammond WJ; Lalazar G; Saltsman JA; Farber BA; Danzer E; Sherpa TC; Banda CD; Andolina JR; Karimi S; Brennan CW; Torbenson MS; La Quaglia MP; Simon SM
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins.
    Averill AM; Rehman HT; Charles JW; Dinh TA; Danyal K; Verschraegen CF; Stein GS; Dostmann WR; Ramsey JE
    J Cell Biochem; 2019 Aug; 120(8):13783-13791. PubMed ID: 30938854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene Rearrangement and Expression of PRKACA and PRKACB Govern Morphobiology of Pancreatobiliary Oncocytic Neoplasms.
    Itoh T; Omori Y; Seino M; Hirose K; Date F; Ono Y; Mizukami Y; Aoki S; Ishida M; Mizuma M; Morikawa T; Higuchi R; Honda G; Okamura Y; Kinoshita K; Unno M; Furukawa T
    Mod Pathol; 2024 Jan; 37(1):100358. PubMed ID: 37871652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
    Rüland L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
    Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.
    Riggle KM; Riehle KJ; Kenerson HL; Turnham R; Homma MK; Kazami M; Samelson B; Bauer R; McKnight GS; Scott JD; Yeung RS
    Pediatr Res; 2016 Jul; 80(1):110-8. PubMed ID: 27027723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A.
    Olivieri C; Walker C; Karamafrooz A; Wang Y; Manu VS; Porcelli F; Blumenthal DK; Thomas DD; Bernlohr DA; Simon SM; Taylor SS; Veglia G
    Commun Biol; 2021 Mar; 4(1):321. PubMed ID: 33692454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in fibrolamellar hepatocellular carcinoma: a review.
    Lim II; Farber BA; LaQuaglia MP
    Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR1 and FGFR2 in fibrolamellar carcinoma.
    Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
    Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A framework for fibrolamellar carcinoma research and clinical trials.
    Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
    Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells.
    Oikawa T; Wauthier E; Dinh TA; Selitsky SR; Reyna-Neyra A; Carpino G; Levine R; Cardinale V; Klimstra D; Gaudio E; Alvaro D; Carrasco N; Sethupathy P; Reid LM
    Nat Commun; 2015 Oct; 6():8070. PubMed ID: 26437858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
    Abou-Alfa GK; Mayer R; Venook AP; O'Neill AF; Beg MS; LaQuaglia M; Kingham PT; Kobos R; Basturk O; Brennan C; Yopp A; Harding JJ; Leong S; Crown J; Hoti E; Leonard G; Ly M; Bradley M; Valentino E; Markowitz D; Zukiwski A; Ren K; Gordan JD
    Oncologist; 2020 Dec; 25(12):e1837-e1845. PubMed ID: 32154962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
    Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
    Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
    Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
    Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
    Graham RP; Torbenson MS
    Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.